Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5668-5673

  Pander, Jan ^a   Heusinkveld, Moniek ^a   Van Der Straaten, Tahar ^a   Jordanova, Ekaterina S ^a   Baak Pablo, Reneé ^a   Gelderblom, Hans ^a   Morreau, Hans ^a   Van Der Burg, Sjoerd H ^a   Guchelaar, Henk Jan ^a   Van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD16 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PROGRAMMED DEATH 1 LIGAND 1; RITUXIMAB; VASCULOTROPIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL ARTICLE; COCULTURE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SPECIFICITY; DRUG TARGETING; FCGR3A GENE; GENE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE ACTIVATION; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR PROMOTION;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD274; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION; MACROPHAGES; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; RECEPTORS, IGG; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052490775     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0239     Document Type: Article

References (23)

1. Weiner L.M., Dhodapkar M.V., Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009;373:1033-1040
2. Bibeau F., Lopez-Crapez E., Di F.F., Thezenas S., Ychou M., Blanchard F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-1129
3. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-758 (Pubitemid 34525533)
4. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/ neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796
5. López-Albaitero A., Lee S.C., Morgan S., Grandis J.R., Gooding W.E., Ferrone S., et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009;58:1853-1864
6. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572
7. Pander J., Gelderblom H., Antonini N.F., Tol J., Van Krieken J.H., Van der Straaten T., et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010;46:1829-1834
8. Kang J.C., Chen J.S., Lee C.H., Chang J.J., Shieh Y.S. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol 2010;102:242-248
9. Nagorsen D., Voigt S., Berg E., Stein H., Thiel E., Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: Relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007;5:62.
10. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 2010;11: 889-896
11. Andreu P., Johansson M., Affara N.I., Pucci F., Tan T., Junankar S., et al. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010;17:121-134
12. Van Dongen M., Savage N.D., Jordanova E.S., Briaire-de Bruijn I.H., Walburg K.V., Ottenhoff T.H., et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitortreated gastrointestinal stromal tumors. Int J Cancer 2010;127: 899-909.
13. Kurai J., Chikumi H., Hashimoto K., Yamaguchi K., Yamasaki A., Sako T., et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-1561 (Pubitemid 46450447)
14. Leidi M., Gotti E., Bologna L., Miranda E., Rimoldi M., Sica A., et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009;182:4415-4422
15. Tonra J.R., Deevi D.S., Corcoran E., Li H., Wang S., Carrick F.E., et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006;12:2197-2207
16. Shaheen R.M., Ahmad S.A., Liu W., Reinmuth N., Jung Y.D., Tseng W.W., et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-589 (Pubitemid 32808285)
17. Jung Y.D., Mansfield P.F., Akagi M., Takeda A., Liu W., Bucana C.D., et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-1140 (Pubitemid 34468020)
18. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the Treatment of Colorectal Cancer. New Engl J Med 2007;357:2040-2048 (Pubitemid 350106711)
19. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417
20. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-3718 (Pubitemid 47372612)
21. Correale P., Marra M., Remondo C., Migali C., Misso G., Arcuri F.P., et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targetedantibody-dependentcell-mediated-cytotoxicity (ADCC). Eur J Cancer 2010;46:1703-1711
22. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
23. Griggs J., Zinkewich-Peotti K. The state of the art: Immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer 2009;101:1807-1812